Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of HPLC Method for the Purity Test by Design of Experiments and Determination of Activation Energy of Hydrolytic Degradation Reactions of Sofosbuvir

Author(s): Jakub Petřík*, Jakub Heřt, Pavel Řezanka, Filip Vymyslický and Michal Douša

Volume 16, Issue 7, 2020

Page: [976 - 987] Pages: 12

DOI: 10.2174/1573412915666190225161007

Price: $65

Abstract

Background: The present study was focused on the development of HPLC method for purity testing of sofosbuvir by the Design of Experiments and determination of the activation energy of hydrolytic degradation reactions of sofosbuvir using HPLC based on the kinetics of sofosbuvir degradation.

Methods: Following four factors for the Design of Experiments were selected, stationary phase, an organic modifier of the mobile phase, column temperature and pH of the mobile phase. These factors were examined in two or three level experimental design using Modde 11.0 (Umetrics) software. The chromatographic parameters like resolution, USP tailing and discrimination factor were calculated and analysed by partial least squares. The chromatography was performed based on Design of Experiments results with the mobile phase containing ammonium phosphate buffer pH 2.5 and methanol as an organic modifier. Separation was achieved using gradient elution on XBridge BEH C8 at 50 °C and a flow rate of 0.8 mL/min. UV detection was performed at 220 nm. The activation energy of hydrolytic degradation reactions of sofosbuvir was evaluated using two different calculation methods. The first method is based on the slope of dependence of natural logarithm of the rate constant on inverted thermodynamic temperature and the second approach is the isoconversional method.

Results and Conclusion: Calculated activation energies were 77.9 ± 1.1 kJ/mol for the first method and 79.5 ± 3.2 kJ/mol for the isoconversional method. The results can be considered to be identical, therefore both calculation methods are suitable for the determination of the activation energy of degradation reactions.

Keywords: Degradation, sofosbuvir, HPLC, purity test, activation energy, kinetics.

« Previous
Graphical Abstract

[1]
Yancey, A.; Armbruster, A.; Tackett, S. Sofosbuvir, a new nucleotide analogue, for the treatment of chronic hepatitis c infection. J. Pharm. Technol., 2014, 31(1), 29-37.
[http://dx.doi.org/10.1177/8755122514548897]
[2]
patent situation of key products for treatment of hepatitis c - sofosbuvir, who,, 2014.
[3]
Baertschi, S.W. ; E, LIlly. Pharmaceutical Stress Testing - Predicting Drug Degradation, 1st ed; Taylor & Francis Group: Boca Raton, 2005.
[http://dx.doi.org/10.1201/9780849359194]
[4]
Swain, D.; Samanthula, G.; Bhagat, S.; Bharatam, P.V.; Akula, V.; Sinha, B.N. Characterization of forced degradation products and in silico toxicity prediction of Sofosbuvir: A novel HCV NS5B polymerase inhibitor. J. Pharm. Biomed. Anal., 2016, 120, 352-363.
[http://dx.doi.org/10.1016/j.jpba.2015.12.045] [PMID: 26771133]
[5]
Bakhti, H.; Hamida, N.B. Kinetics and mechanism of degradation of aqueous promecarb insecticide studied by UV spectrophotometry and HPLC. Prog. React. Kinet. Mech., 2017, 42(2), 145-153.
[http://dx.doi.org/10.3184/146867817X14821527548933]
[6]
Pan, J.; Gong, X.; Qu, H. Degradation kinetics and mechanism of lithospermic acid under low oxygen condition using quantitative 1H NMR with HPLC-MS. PLoS One, 2016, 11(10) e0164421
[http://dx.doi.org/10.1371/journal.pone.0164421] [PMID: 27776128]
[7]
Kishore, R.S.K.; Pappenberger, A.; Dauphin, I.B.; Ross, A.; Buergi, B.; Staempfli, A.; Mahler, H.C. Degradation of polysorbates 20 and 80: studies on thermal autoxidation and hydrolysis. J. Pharm. Sci., 2011, 100(2), 721-731.
[http://dx.doi.org/10.1002/jps.22290] [PMID: 20803573]
[8]
Oliyai, R.; Lindenbaum, S. Stability testing of pharmaceuticals by isothermal heat conduction calorimetry: Ampicilin in aqueous solution. Int. J. Pharm., 1991, 73, 33-36.
[http://dx.doi.org/10.1016/0378-5173(91)90097-8]
[9]
Atkins, P.; de Paula, J. Atkins; Oxford University Press: Physical Chemistry, Great Britain, 2006.
[10]
Ishida, H.; Rodriguez, Y. Curing kinetics of a new benzoxazinebased phenolic resin by differential scanning calorimetry. Polymer (Guildf.), 1995, 36, 3151-3158.
[http://dx.doi.org/10.1016/0032-3861(95)97878-J]
[11]
Eriksson, L.; Johansson, E.; Kettaneh-Wold, N.; Wikstrom, C.; Wold, S. Design of Experiments: Principles and Aplications; LEARWAYS AB: Stockholm, 2000.
[12]
Cavazzuti, M. Optimization Methods: From Theory to Design Scientific and Technological Aspects in Mechanics; Springer-Verlag: Berlin, 2013.
[http://dx.doi.org/10.1007/978-3-642-31187-1]
[13]
Sahu, P.K.; Ramisetti, N.R.; Cecchi, T.; Swain, S.; Patro, C.S.; Panda, J. An overview of experimental designs in HPLC method development and validation. J. Pharm. Biomed. Anal., 2018, 147, 590-611.
[http://dx.doi.org/10.1016/j.jpba.2017.05.006] [PMID: 28579052]
[14]
Douša, M.; Gibala, P.; Pekárek, T. New approach of validation using internal normalization technique for quantification of related substances in raw material, intermediates and pharmaceutical substances by HPLC. J. Pharm. Biomed. Anal., 2015, 114, 133-138.
[http://dx.doi.org/10.1016/j.jpba.2015.05.015] [PMID: 26037162]
[15]
international conference on harmonisation: validation of analytical procedures: text and methodology ich q2(r1), ich,, 2005.
[16]
Convention, U.S.P. United States Pharmacopoeia 41 - National Formulary 36; United States Pharmacopoeia: Rockville, 2018, pp. 6370-6371.
[17]
Falah, M.Z.; Martin, M. Influence of the peak height distribution on separation performances: discrimination factor and efective peak capacity. Chromatographia, 1987, 24, 115-122.
[http://dx.doi.org/10.1007/BF02688473]

Rights & Permissions Print Cite
Article Metrics
25
© 2024 Bentham Science Publishers | Privacy Policy